标题
Alogliptin benzoate for the treatment of type 2 diabetes
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 13, Issue 4, Pages 553-563
出版商
Informa Healthcare
发表日期
2012-02-02
DOI
10.1517/14656566.2012.656088
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Alogliptin: a new addition to the class of DPP-4 inhibitors
- (2016) Marc Rendell Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
- (2011) Antonio R Chacra et al. Diabetes & Vascular Disease Research
- Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
- (2011) Priscilla L Hollander et al. Diabetes & Vascular Disease Research
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects
- (2011) A. Karim et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- The Safety of Incretin-Based Therapies—Review of the Scientific Evidence
- (2011) Daniel J. Drucker et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Linagliptin: A New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
- (2011) Peter P. Toth POSTGRADUATE MEDICINE
- Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes
- (2011) Chetan Karyekar et al. POSTGRADUATE MEDICINE
- Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 Diabetes
- (2010) N. L. Borja-Hart et al. ANNALS OF PHARMACOTHERAPY
- Dipeptidylpeptitase-4 Inhibitors (Gliptins)
- (2010) André J. Scheen CLINICAL PHARMACOKINETICS
- Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects
- (2010) Akiko Sarashina et al. CLINICAL THERAPEUTICS
- Counterpoint: Intensive Glucose Control and Mortality in ACCORD--Still Looking for Clues
- (2010) M. C. Riddle DIABETES CARE
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
- (2010) T. Forst et al. DIABETIC MEDICINE
- Alogliptin
- (2010) Lesley J. Scott DRUGS
- Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
- (2010) B. Göke et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
- (2010) Faramarz Ismail-Beigi et al. LANCET
- Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
- (2009) Joshua J Neumiller et al. ANNALS OF PHARMACOTHERAPY
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2009) Richard E. Pratley et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
- (2009) Debora Williams-Herman et al. CURRENT MEDICAL RESEARCH AND OPINION
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
- (2009) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
- (2009) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
- (2009) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants
- (2009) Aziz Karim et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Studies of Liraglutide, a Novel, Once-Daily Human Glucagon-Like Peptide-1 Analog for Improved Management of Type 2 Diabetes Mellitus
- (2009) Scott R Drab PHARMACOTHERAPY
- Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
- (2008) P COVINGTON et al. CLINICAL THERAPEUTICS
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
- (2008) Itamar Raz et al. CURRENT MEDICAL RESEARCH AND OPINION
- Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials
- (2008) Avraham Karasik et al. CURRENT MEDICAL RESEARCH AND OPINION
- Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials
- (2008) Sten Madsbad et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
- (2008) R. A. DeFronzo et al. DIABETES CARE
- Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
- (2008) B. F. Burkey et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*
- (2008) R. Scott et al. DIABETES OBESITY & METABOLISM
- Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Vildagliptin
- (2008) Jamie D Croxtall et al. DRUGS
- Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin
- (2008) B. Göke et al. HORMONE AND METABOLIC RESEARCH
- Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
- (2008) M. A. Nauck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
- AMH (Australian Medicines Handbook, 2007 Edition)
- (2007) S E Tett CLINICAL PHARMACOLOGY & THERAPEUTICS
- Postmenopausal Hormone Therapy for Disease Prevention: Have We Learned Any Lessons from the Past?
- (2007) J E Rossouw CLINICAL PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started